Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Gagelmann, N, Eikema, D-J, Stelljes, M, Beelen, D, de Wreede, L, Mufti, G, Knelange, NS, Niederwieser, D, Friis, LS, Ehninger, G, Nagler, A, Yakoub-Agha, I, Meijer, E, Ljungman, P, Maertens, J, Kanz, L, Lopez-Corral, L, Brecht, A, Craddock, C, Finke, J, Cornelissen, JJ, Bernasconi, P, Chevallier, P, Sierra, J, Robin, M & Kröger, N 2019, 'Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation' Haematologica, bind 104, nr. 5, s. 929-936. https://doi.org/10.3324/haematol.2018.200808

APA

Gagelmann, N., Eikema, D-J., Stelljes, M., Beelen, D., de Wreede, L., Mufti, G., ... Kröger, N. (2019). Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica, 104(5), 929-936. https://doi.org/10.3324/haematol.2018.200808

CBE

Gagelmann N, Eikema D-J, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N. 2019. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 104(5):929-936. https://doi.org/10.3324/haematol.2018.200808

MLA

Vancouver

Author

Gagelmann, Nico ; Eikema, Diderik-Jan ; Stelljes, Matthias ; Beelen, Dietrich ; de Wreede, Liesbeth ; Mufti, Ghulam ; Knelange, Nina Simone ; Niederwieser, Dietger ; Friis, Lone S ; Ehninger, Gerhard ; Nagler, Arnon ; Yakoub-Agha, Ibrahim ; Meijer, Ellen ; Ljungman, Per ; Maertens, Johan ; Kanz, Lothar ; Lopez-Corral, Lucia ; Brecht, Arne ; Craddock, Charles ; Finke, Jürgen ; Cornelissen, Jan J ; Bernasconi, Paolo ; Chevallier, Patrice ; Sierra, Jorge ; Robin, Marie ; Kröger, Nicolaus. / Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. I: Haematologica. 2019 ; Bind 104, Nr. 5. s. 929-936.

Bibtex

@article{01064b3d82ed426a93d0b2ba6f64c71e,
title = "Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation",
abstract = "The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90{\%}, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1{\%}, and platelet count ≤50 × 109/L prior to transplantation. Incorporating these factors into a four-level risk score yielded hazard ratios for death, with low-risk (score of 0-1) as reference, of 2.02 (95{\%} CI: 1.41-2.90) for the intermediate-risk group (score of 2-3), 3.49 (95{\%} CI: 2.45-4.97) for the high-risk group (score of 4-5), and 5.90 (95{\%} CI: 4.01-8.67) for the very high-risk group (score of >5). The score was predictive of survival, relapse-free survival, relapse, and non-relapse mortality (P<0.001, respectively). Cross-validation yielded significant and reproducible improvement in prognostic ability with C-statistics being 0.609 (95{\%} CI: 0.588-0.629) versus 0.555 for the Gruppo Italiano Trapianto di Midollo Osseo registry and 0.579 for the Center for Blood and Marrow Transplant Research registry. Prediction was even further augmented after applying a nomogram using age and platelets as continuous variables showing C-statistics of 0.628 (95{\%} CI: 0.616-0.637). In conclusion, compared to existing prognostic systems, this proposed transplant-specific risk score offers improved performance with respect to post-transplant risk stratification in myelodysplastic syndromes.",
author = "Nico Gagelmann and Diderik-Jan Eikema and Matthias Stelljes and Dietrich Beelen and {de Wreede}, Liesbeth and Ghulam Mufti and Knelange, {Nina Simone} and Dietger Niederwieser and Friis, {Lone S} and Gerhard Ehninger and Arnon Nagler and Ibrahim Yakoub-Agha and Ellen Meijer and Per Ljungman and Johan Maertens and Lothar Kanz and Lucia Lopez-Corral and Arne Brecht and Charles Craddock and J{\"u}rgen Finke and Cornelissen, {Jan J} and Paolo Bernasconi and Patrice Chevallier and Jorge Sierra and Marie Robin and Nicolaus Kr{\"o}ger",
note = "Copyright{\circledC} 2019 Ferrata Storti Foundation.",
year = "2019",
month = "5",
doi = "10.3324/haematol.2018.200808",
language = "English",
volume = "104",
pages = "929--936",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Fondazione/Ferrata Storti",
number = "5",

}

RIS

TY - JOUR

T1 - Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

AU - Gagelmann, Nico

AU - Eikema, Diderik-Jan

AU - Stelljes, Matthias

AU - Beelen, Dietrich

AU - de Wreede, Liesbeth

AU - Mufti, Ghulam

AU - Knelange, Nina Simone

AU - Niederwieser, Dietger

AU - Friis, Lone S

AU - Ehninger, Gerhard

AU - Nagler, Arnon

AU - Yakoub-Agha, Ibrahim

AU - Meijer, Ellen

AU - Ljungman, Per

AU - Maertens, Johan

AU - Kanz, Lothar

AU - Lopez-Corral, Lucia

AU - Brecht, Arne

AU - Craddock, Charles

AU - Finke, Jürgen

AU - Cornelissen, Jan J

AU - Bernasconi, Paolo

AU - Chevallier, Patrice

AU - Sierra, Jorge

AU - Robin, Marie

AU - Kröger, Nicolaus

N1 - Copyright© 2019 Ferrata Storti Foundation.

PY - 2019/5

Y1 - 2019/5

N2 - The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 × 109/L prior to transplantation. Incorporating these factors into a four-level risk score yielded hazard ratios for death, with low-risk (score of 0-1) as reference, of 2.02 (95% CI: 1.41-2.90) for the intermediate-risk group (score of 2-3), 3.49 (95% CI: 2.45-4.97) for the high-risk group (score of 4-5), and 5.90 (95% CI: 4.01-8.67) for the very high-risk group (score of >5). The score was predictive of survival, relapse-free survival, relapse, and non-relapse mortality (P<0.001, respectively). Cross-validation yielded significant and reproducible improvement in prognostic ability with C-statistics being 0.609 (95% CI: 0.588-0.629) versus 0.555 for the Gruppo Italiano Trapianto di Midollo Osseo registry and 0.579 for the Center for Blood and Marrow Transplant Research registry. Prediction was even further augmented after applying a nomogram using age and platelets as continuous variables showing C-statistics of 0.628 (95% CI: 0.616-0.637). In conclusion, compared to existing prognostic systems, this proposed transplant-specific risk score offers improved performance with respect to post-transplant risk stratification in myelodysplastic syndromes.

AB - The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 × 109/L prior to transplantation. Incorporating these factors into a four-level risk score yielded hazard ratios for death, with low-risk (score of 0-1) as reference, of 2.02 (95% CI: 1.41-2.90) for the intermediate-risk group (score of 2-3), 3.49 (95% CI: 2.45-4.97) for the high-risk group (score of 4-5), and 5.90 (95% CI: 4.01-8.67) for the very high-risk group (score of >5). The score was predictive of survival, relapse-free survival, relapse, and non-relapse mortality (P<0.001, respectively). Cross-validation yielded significant and reproducible improvement in prognostic ability with C-statistics being 0.609 (95% CI: 0.588-0.629) versus 0.555 for the Gruppo Italiano Trapianto di Midollo Osseo registry and 0.579 for the Center for Blood and Marrow Transplant Research registry. Prediction was even further augmented after applying a nomogram using age and platelets as continuous variables showing C-statistics of 0.628 (95% CI: 0.616-0.637). In conclusion, compared to existing prognostic systems, this proposed transplant-specific risk score offers improved performance with respect to post-transplant risk stratification in myelodysplastic syndromes.

U2 - 10.3324/haematol.2018.200808

DO - 10.3324/haematol.2018.200808

M3 - Journal article

VL - 104

SP - 929

EP - 936

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -

ID: 59180615